The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

A third monoclonal antibody product to protect babies against respiratory syncytial virus was approved by the Food and Drug Administration on Monday, a development public health experts hope may ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season ...